|
| Index | - | P/E | - | EPS (ttm) | -2.48 | Insider Own | 9.02% | Shs Outstand | 10.23M | Perf Week | 15.77% |
| Market Cap | 105.70M | Forward P/E | - | EPS next Y | -1.26 | Insider Trans | 1.00% | Shs Float | 3.32M | Perf Month | -15.57% |
| Income | -25.30M | PEG | - | EPS next Q | -0.54 | Inst Own | 90.40% | Short Float | 4.75% | Perf Quarter | -30.58% |
| Sales | 42.70M | P/S | 2.48 | EPS this Y | -112.20% | Inst Trans | 0.01% | Short Ratio | 8.37 | Perf Half Y | 2.23% |
| Book/sh | 2.04 | P/B | 5.40 | EPS next Y | 36.30% | ROA | - | Target Price | 20.00 | Perf Year | - |
| Cash/sh | 4.08 | P/C | 2.70 | EPS next 5Y | - | ROE | - | 52W Range | 9.31 - 18.20 | Perf YTD | -19.22% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | -31.00% | 52W High | -39.51% | Beta | - |
| Dividend % | - | Quick Ratio | 1.90 | Sales past 5Y | - | Gross Margin | 48.20% | 52W Low | 18.26% | ATR | 0.80 |
| Employees | 163 | Current Ratio | 2.20 | Sales Q/Q | 12.60% | Oper. Margin | -30.00% | RSI (14) | 42.49 | Volatility | 10.60% 6.55% |
| Optionable | No | Debt/Eq | 1.47 | EPS Q/Q | -72.60% | Profit Margin | -53.30% | Rel Volume | 0.70 | Prev Close | 11.03 |
| Shortable | Yes | LT Debt/Eq | 0.86 | Earnings | May 04 AMC | Payout | - | Avg Volume | 18.83K | Price | 11.01 |
| Recom | 2.00 | SMA20 | -5.60% | SMA50 | -16.43% | SMA200 | -18.13% | Volume | 13,191 | Change | -0.18% |
 | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite